Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately.

In trading on Tuesday, shares of Globus Medical Inc (Symbol ... for entry point opportunities on the buy side. The chart below shows the one year performance of GMED shares: Looking at the ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. The firm had revenue of $657.29 million during the quarter, compared to analysts’ expectations of $646.19 million.

AUDUBON, Pa. - Globus Medical, Inc. (NYSE: GMED), a prominent musculoskeletal technology company with a market capitalization of $10.08 billion and impressive revenue growth of 60.62% in the last ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Globus Medical (GMED – Research Report) yesterday and set a price target of $101.00. The company’s shares closed yesterday at ...

Globus Medical, Inc. (NYSE:GMED – Free Report) – Research analysts at Roth Capital lowered their Q1 2025 earnings estimates for Globus Medical in a research report issued to clients and ...